<DOC>
	<DOC>NCT02161315</DOC>
	<brief_summary>Steroid Aromatase Inhibitors and Non-Steroid Aromatase Inhibitors in Late Stage Breast Cancer is the recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. In the past controlled clinical trials with small sample.</brief_summary>
	<brief_title>Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer</brief_title>
	<detailed_description>A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer.The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Progestins</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>1. Patients must be the postmenopausal women 2. Patients must be diagnosed with advanced breast cancer by imageologyï¼Œcytology or histopathology 3. Immunohistochemistry shows ER and/or PR positive 4. Patients ECOG score must be 02 5. Drug resistant about NonSteroid Aromatase Inhibitors 1. Not suitable for endocrine therapy 2. Have receive the standard Steroid Aromatase Inhibitors treatment 3. Severe hepatic dysfunction</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>SAID, Progestogens, nSAID-resistanced, LSBC</keyword>
</DOC>